Homology Medicines is a genetic medicines company in Massachusetts that focuses on patients suffering from rare genetic diseases. Founded 2015 in Lexington, Massachusetts, United States by Laura Smith and Saswati Chatterjee, Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. The company has a suite of 15 AAVHSC patents, including a proprietary gene editing and gene therapy platform for rare diseases.
The company has developed a novel set of adeno-associated virus vectors derived from human hematopoietic stem cells (AAVHSCs) that are designed to precisely and efficiently deliver genetic medicines in vivo either through gene therapy or by harnessing the body’s natural DNA repair process of homologous recombination through nuclease-free gene editing.
Scientific Co-founder & Project Lead Scientist